Lloyd Mitchell Segal - Jun 3, 2021 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role
President and CEO
Signature
/s/ Steve Forte, Attorney-in-Fact
Stock symbol
RPTX
Transactions as of
Jun 3, 2021
Transactions value $
-$1,267,182
Form type
4
Date filed
6/7/2021, 06:36 PM
Previous filing
May 21, 2021
Next filing
Jun 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Stock Sale -$211K -6.65K -4.98% $31.74 127K Jun 3, 2021 See footnote F1, F2
transaction RPTX Common Stock Sale -$526K -17.2K -13.53% $30.64 110K Jun 4, 2021 See footnote F2, F3
transaction RPTX Common Stock Sale -$382K -12.2K -11.09% $31.36 97.6K Jun 4, 2021 See footnote F2, F4
transaction RPTX Common Stock Options Exercise $8.19K +5K +100% $1.64* 10K Jun 4, 2021 Direct
transaction RPTX Common Stock Sale -$156K -5K -50% $31.25 5K Jun 4, 2021 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPTX Employee Stock Option (right to buy) Options Exercise $0 -5K -1.73% $0.00 284K Jun 4, 2021 Common Stock 5K $1.64 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5).
F2 These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.19 inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.215 to $31.65 inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.49 inclusive.
F6 Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.